# Semax vs Selank: what the evidence separates

> Semax and Selank compared on what was measured: small Russian studies, no head-to-head clinical trial, one shared fMRI study and different FDA histories.

Source page: https://peptioresearch.com/articles/semax-vs-selank/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-11
Type: Comparison

Semax and Selank are two different peptides, and no study comparing them in patients was found. Both rest on small, mostly Russian studies, and none of the patient studies described below has an abstract that describes random allocation and blinding against placebo with a clinical outcome. The only study found that gave both to people scanned 52 healthy participants by fMRI, a brain imaging method, and measured resting-state connectivity, not memory, attention or anxiety [1]. Its abstract describes "general and specific effects of Selank and Semax" and does not rank one above the other.

## Side by side

| | Semax | Selank |
|---|---|---|
| Sequence | MEHFPGP | TKPRPGP |
| Described as | analogue of the ACTH 4-10 fragment | synthetic analogue of tuftsin |
| Studied in patients | stroke, eye disease, motor neuron disease, peptic ulcer, posthypoxic encephalopathy | anxiety disorders and neurasthenia; blood from patients with depression in one laboratory study |
| Best design found in patients | comparisons not described as randomised; one open-label; some uncontrolled | comparisons with a benzodiazepine, no placebo arm |
| In healthy people | fMRI only | fMRI only, in the shared study |
| FDA advisory committee | considered 24 July 2026; briefing weighs against the 503A list; HHS states the committee voted in favour | on no agenda found |
| HHS enforcement policy, October 2026 | semax free base covered for compounders under ten conditions; not an approval | not covered |
| FDA withdrawn-nominations table | listed | listed |
| Russian registration | reported by FDA, second hand | not established |

Each row is sourced in the sections below.

## What each is

Semax is a chain of seven amino acids, Met-Glu-His-Phe-Pro-Gly-Pro, as FDA's briefing gives it [2]. Published studies describe it as an analogue of the 4-10 fragment of adrenocorticotropic hormone (ACTH), the pituitary hormone that drives cortisol release [3].

Selank is also seven amino acids, Thr-Lys-Pro-Arg-Pro-Gly-Pro [4]. It is a synthetic analogue of tuftsin, a four-amino-acid fragment of the human immunoglobulin G heavy chain, lengthened by Pro-Gly-Pro [5].

That Pro-Gly-Pro tail is what the two share. The rest of the sequence differs, and so does the starting peptide: a hormone fragment in one case, an immunoglobulin fragment in the other.

## What was measured in people

### Semax

In 110 patients after ischaemic stroke, a comparison whose abstract does not describe randomisation reported higher plasma BDNF, a neurotrophic factor measured in blood, and better Barthel index scores of daily living with semax added to rehabilitation; the abstract gives no effect sizes [6]. Earlier studies, of 30 stroke patients against 80 controls and of 187 patients with cerebrovascular insufficiency and no stated comparator, report faster recovery on neurological scales the abstracts do not name [7] [8].

In 27 people with motor neuron disease, an open-label study found no effect on needle EMG or two ALS rating scales, and better scores only on ALSAQ-40, a patient-reported quality of life questionnaire [9]. In people with refractory peptic ulcer, healing at day 14 was reported in 89.5% with semax added to standard drugs against 30.8% on standard drugs alone, in an abstract that gives no sample size or allocation method [10]. Russian studies in eye disease report better visual acuity, visual field or electrophysiological measures, mostly with semax added to other treatment [11] [12].

In healthy people, the placebo-controlled work measured brain networks by fMRI. In 24 healthy volunteers, 10 of them on placebo, Lebedeva and colleagues report a larger medial frontal part of the default mode network, a set of brain regions active at rest [13]. No abstract found tested memory or attention against placebo in healthy people.

### Selank

Selank has been tested in four small Russian studies of patients with anxiety disorders, none with a placebo arm [14] [15] [16] [17]. In 62 patients with generalised anxiety disorder or neurasthenia, selank (30 patients) and the benzodiazepine medazepam (32 patients) were scored on the Hamilton, Zung and CGI scales, and the authors call the anxiolytic effects "similar" [14]. In 60 patients with phobic-anxiety and somatoform disorders, a comparison with phenazepam reports "mild nootropic effects" of selank without naming a cognitive test, and gives no result for phenazepam [15].

In 70 patients with anxiety-phobic, hypochondriac and somatoform disorders, selank added to phenazepam (40) against phenazepam alone (30) is reported to bring forward improvement on the HDRS and to reduce phenazepam's side effects on the UKU scale [16]. That design tests selank alongside a benzodiazepine, not on its own. The fourth study measured immune laboratory markers, not symptoms [17].

> **Evidence (Human case report).**
> PubMed tags the semax motor neuron disease study and two of the selank anxiety studies as randomised controlled trials, but their abstracts describe an open-label design or do not mention randomisation or blinding [9] [14] [16].

> **Limitation.**
> For both peptides only English abstracts were read. Scores, durations and adverse events are mostly absent, and most of the work comes from Russian research groups.

## The one study that included both

Panikratova and colleagues scanned 52 healthy participants given selank, semax or placebo, before and 5 and 20 minutes after administration, and report differences in functional connectivity of the right amygdala [1]. No anxiety, memory or attention measure was reported, and the abstract does not state arm sizes, randomisation or blinding.

> **Key point.**
> The only study found with both peptides measured brain connectivity in healthy people, not a clinical outcome. It is not a head-to-head trial of either peptide for cognition or anxiety [1].

FDA's briefing notes that the semax participants in this study and in the earlier 24-person fMRI study "appear to be very similar" and that it is unclear whether the same people took part in both [2]. The two samples are not added together here.

## FDA

FDA lists both in its table of bulk drug substances nominated for compounding but withdrawn, with separate wording for each. For semax it states the agency "lacks sufficient information to know whether the drug would cause harm if administered to humans"; for selank acetate it states that FDA "lacks important information regarding any safety issues raised by selank acetate administered to humans" [18]. Neither has an entry in any category of the 503A bulk drug substance list updated on 14 May 2026 [19].

The histories then diverge. FDA's Pharmacy Compounding Advisory Committee considered semax free base and semax acetate on 24 July 2026 for cerebral ischaemia, migraine and trigeminal neuralgia [20]. FDA's briefing concludes that "a balancing of the criteria weighs against" placing semax on the 503A list, resting "in particular" on semax not being well characterised physicochemically, and finds that the two references it could assess "demonstrated lack of effectiveness" for those uses [2]. A trade journal and a law firm, both second hand, report that the committee nonetheless voted to recommend semax for the list, without giving the count; FDA had posted no vote record by 6 November 2026 [20], and a recommendation does not put a substance on the list [21]. HHS's October 2026 enforcement policy says the committee voted in favour, and that HHS does not intend to act against compounders of semax free base, for intranasal use, who meet ten listed conditions [22]. The notice calls that policy a non-binding draft [23]. Selank is not among its six substances [22]. Selank was not on the July 2026 agenda or on the one FDA lists for before the end of February 2027, and no FDA briefing on selank was found [20] [24].

On Russian registration, FDA's briefing states that "Semax is a registered drug in Russia", citing the Russian State Register; this site could not retrieve the register entry [2]. For selank, the only source found is a table in a 2022 review that lists it as an anxiolytic among peptide drugs developed in Russia, without a registration number, date or indication, so its registration is not established here [25]. Registration in Russia, where reported, is not approval elsewhere.

> **Caution.**
> FDA states that compounded products of either peptide may carry a risk of immune reactions for certain routes, because of aggregation and peptide-related impurities [18]. No human pharmacokinetic study was found for either; for semax, FDA states it could not find one by any route [2].

## What is not known

Searches found no registered trial and no systematic review for either peptide. No placebo-controlled study with a clinical outcome was found in patients for either, and no study was found that compared the two on memory, attention, anxiety or any other clinical endpoint. The claim that semax improves memory and attention in healthy people traces, in the sources found, to a 1997 overview by its developers that names no test or sample size [26]. The claim that selank acts on GABA-A receptors is a hypothesis in the sources found: in rat frontal cortex, selank or GABA changed the expression of 45 genes, with no count for selank alone, while a human cell line showed no change [5] [27].

On the evidence found, the two cannot be ranked against each other for any outcome in people.

## Sources

1. Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020. https://doi.org/10.1134/S001249662001007X
2. FDA Briefing Document: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/193348/download
3. Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. https://doi.org/10.1016/j.brainres.2006.07.108
4. Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001. https://doi.org/10.1023/a:1017979514274
5. Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016. https://doi.org/10.3389/fphar.2016.00031
6. Gusev EI et al. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018. https://doi.org/10.17116/jnevro20181183261-68
7. Gusev EI et al. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1997. https://pubmed.ncbi.nlm.nih.gov/11517472/
8. Gusev EI, Skvortsova VI, Chukanova EI. [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2005. https://pubmed.ncbi.nlm.nih.gov/15792140/
9. Serdiuk AV et al. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2007. https://pubmed.ncbi.nlm.nih.gov/18379501/
10. Ivanikov IO et al. Therapy of peptic ulcer with semax peptide. Bulletin of Experimental Biology and Medicine. 2002. https://doi.org/10.1023/a:1020621124776
11. Nazarova GA et al. [The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2013. https://pubmed.ncbi.nlm.nih.gov/24437205/
12. Dragon AK et al. [Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2022. https://doi.org/10.17116/kurort20229904272
13. Lebedeva IS et al. Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine. 2018. https://doi.org/10.1007/s10517-018-4234-3
14. Zozulia AA et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008. https://pubmed.ncbi.nlm.nih.gov/18454096/
15. Medvedev VE et al. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014. https://pubmed.ncbi.nlm.nih.gov/25176261/
16. Medvedev VE et al. [Optimization of the treatment of anxiety disorders with selank]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015. https://doi.org/10.17116/jnevro20151156133-40
17. Uchakina ON et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008. https://pubmed.ncbi.nlm.nih.gov/18577961/
18. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
19. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/94155/download
20. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
21. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know
22. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
23. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526). Federal Register. 2026. https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf
24. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
25. Deigin VI et al. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14040716
26. Asmarin IP et al. [A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova. 1997. https://pubmed.ncbi.nlm.nih.gov/9173745/
27. Filatova E et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017. https://doi.org/10.3389/fphar.2017.00089
